Medicine and Dentistry
Malignant Neoplasm
72%
Clinical Trial
67%
Solid Malignant Neoplasm
59%
Quality of Life
36%
Melanoma
32%
Anticancer Drug
32%
Cancer Therapy
32%
Immunotherapy
32%
Eye Toxicity
32%
Oncology
26%
Targeted Therapy
26%
Progression Free Survival
25%
Diseases
23%
Molecularly Targeted Therapy
21%
Advanced Cancer
20%
Adolescence
19%
Cachexia
18%
Cancer
18%
Female Genital Tract Cancer
16%
Bevacizumab
16%
Systematic Review
16%
4 Iodo 2,5 Dimethoxyamphetamine
16%
Cediranib
16%
Electrocorticography
16%
Vasculotropin
16%
Dasatinib
16%
Pembrolizumab
16%
Patient Population
16%
Gemcitabine
16%
Intermittent Fasting
16%
Meta-Analysis
16%
Nutrition Monitoring
16%
Observational Study
16%
Epidermal Growth Factor Receptor
16%
Lenvatinib
16%
Cell Therapy
16%
Diet
16%
Metastatic Colorectal Cancer
16%
Retreatment
16%
Biopsy Technique
16%
Patient Decision Making
16%
Patient Referral
14%
Effect Size
12%
Diarrhea
12%
Clearance
12%
Odds Ratio
11%
Adverse Event
9%
Diet Therapy
9%
Logistic Regression Analysis
8%
Medicare
8%
Keyphrases
Symptom Burden
35%
Patients with Advanced Cancer
35%
Lenvatinib
32%
Advanced Solid Tumors
32%
Phase 1 Study
32%
Low-income Women
28%
Early Phase Clinical Trials
28%
Solid Tumors
26%
Advanced Melanoma
24%
Molecular Targeted Therapy
24%
Stable Disease
24%
Patient-reported Symptoms
22%
Targeted Therapy
22%
Oncology Clinical Trials
19%
Melanoma Patients
19%
Partial Response
19%
Cancer Treatment
18%
Cancer Cachexia
18%
Odds Ratio
18%
Melanoma
18%
Partial Remission
16%
Phase II Clinical Trial
16%
Food Choice
16%
Pazopanib
16%
Semi-quantitative Food Frequency Questionnaire
16%
Temozolomide
16%
Multikinase Inhibitor
16%
Dose-escalation Study
16%
Early Phase Oncology
16%
Children from Low-income Families
16%
During Pregnancy
16%
Meta-analysis
16%
Online Social Networking
16%
Phase 1b Study
16%
Complete Remission
16%
College Women
16%
Sleep Quality
16%
E7080
16%
Rare Cancer
16%
Gemcitabine
16%
High School Age
16%
School-age Students
16%
Middle School Age
16%
Patient Demographics
16%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
16%
Fatigue Symptoms
16%
BRAF mutation
16%
Southwestern United States
16%
Molecular Aberrations
16%
Lapatinib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Solid Malignant Neoplasm
89%
Melanoma
48%
Adverse Event
45%
Lenvatinib
32%
Diseases
28%
Malignant Neoplasm
28%
Maximum Tolerated Dose
27%
Progression Free Survival
21%
Phase I Trials
21%
Neoplasm
19%
Diarrhea
17%
Advanced Cancer
17%
Pharmacokinetic
17%
Anticancer Drug
16%
Pazopanib
16%
Phosphatidylinositol 3 Kinase Inhibitor
16%
Cediranib
16%
Vasculotropin
16%
Pembrolizumab
16%
Lapatinib
16%
Temozolomide
16%
Gemcitabine
16%
Eye Toxicity
16%
Immunotherapy
16%
Dasatinib
16%
Bevacizumab
16%
Remission
13%
Rash
9%
Mood Disorder
8%
Biological Product
8%
Proteinuria
7%
Brain Hemorrhage
6%
Antitumor Activity
6%
Inflammatory Breast Cancer
5%
Protein Tyrosine Kinase
5%
Haplorhini
5%
Clinical Study
5%
Preclinical Toxicology
5%
Metastatic Melanoma
5%
Angiopoietin 1
5%
Protein P53
5%
Mouse Model
5%